<?xml version="1.0" encoding="utf-8"?><rss version="2.0"><channel><title>Teva Pharmaceutical Industries Ltd. Press Releases </title><link>https://ir.tevapharm.com/</link><description>generated by Q4</description><category /><lastBuildDate>Sun, 15 Nov 2026 18:12:37 -0500</lastBuildDate><copyright>Copyright Q4 Inc. All rights reserved.</copyright><item><title>Teva Shares Innovative Pipeline Updates and Unveils Path to Future Growth at R&amp;D Day, Targeting $6–7 Billion in Innovative Medicines Revenue by 2030</title><guid>6d597226-4bd2-4ce2-a91d-61448949c4f1</guid><description /><link>https://ir.tevapharm.com/news-and-events/press-releases/press-release-details/2026/Teva-Shares-Innovative-Pipeline-Updates-and-Unveils-Path-to-Future-Growth-at-RD-Day-Targeting-67-Billion-in-Innovative-Medicines-Revenue-by-2030/default.aspx</link><pubDate>Wed, 11 Nov 2026 07:30:00 -0500</pubDate></item><item><title>Teva’s Pivot to Growth Strategy Delivers 33% Growth Across Key Innovative Brands; Raises 2026 Outlook for AUSTEDO®, AJOVY® and UZEDY®; Delivers Substantial Gross Margin Expansion</title><guid>d063e483-5e4b-4089-a344-701e00a8fda9</guid><description /><link>https://ir.tevapharm.com/news-and-events/press-releases/press-release-details/2026/Tevas-Pivot-to-Growth-Strategy-Delivers-33-Growth-Across-Key-Innovative-Brands-Raises-2026-Outlook-for-AUSTEDO-AJOVY-and-UZEDY-Delivers-Substantial-Gross-Margin-Expansion/default.aspx</link><pubDate>Tue, 03 Nov 2026 07:00:00 -0500</pubDate></item><item><title>Teva and Samsung Bioepis Announce Agreement to Commercialize Two FDA-Approved Biosimilars in the U.S.</title><guid>364f30a4-0175-40d0-a554-1d2ea28a3d19</guid><description /><link>https://ir.tevapharm.com/news-and-events/press-releases/press-release-details/2026/Teva-and-Samsung-Bioepis-Announce-Agreement-to-Commercialize-Two-FDA-Approved-Biosimilars-in-the-U-S-/default.aspx</link><pubDate>Tue, 03 Nov 2026 05:00:00 -0500</pubDate></item><item><title>Teva to Discontinue Phase 2 TOPAS-MSA Study of emrusolmin (TEV-‘286) Following Interim Futility Analysis</title><guid>ee019b65-f30a-4d6a-a49e-92f552350423</guid><description /><link>https://ir.tevapharm.com/news-and-events/press-releases/press-release-details/2026/Teva-to-Discontinue-Phase-2-TOPAS-MSA-Study-of-emrusolmin-TEV-286-Following-Interim-Futility-Analysis/default.aspx</link><pubDate>Mon, 02 Nov 2026 08:00:00 -0500</pubDate></item><item><title>Teva Acquires Worldwide Rights to BXCL501, Further Expanding Innovative Neuroscience Pipeline</title><guid>612957be-3af5-495c-8913-03ec2d33cb2d</guid><description /><link>https://ir.tevapharm.com/news-and-events/press-releases/press-release-details/2026/Teva-Acquires-Worldwide-Rights-to-BXCL501-Further-Expanding-Innovative-Neuroscience-Pipeline/default.aspx</link><pubDate>Tue, 27 Oct 2026 08:00:00 -0400</pubDate></item><item><title>UEG Week: Teva and Sanofi’s Duvakitug Maintained Long-Term Positive Outcomes in New Phase 2b Data for Ulcerative Colitis and Crohn’s Disease</title><guid>439368a1-32ba-405d-9f3a-151e462276a8</guid><description /><link>https://ir.tevapharm.com/news-and-events/press-releases/press-release-details/2026/UEG-Week-Teva-and-Sanofis-Duvakitug-Maintained-Long-Term-Positive-Outcomes-in-New-Phase-2b-Data-for-Ulcerative-Colitis-and-Crohns-Disease/default.aspx</link><pubDate>Tue, 20 Oct 2026 08:00:00 -0400</pubDate></item><item><title>Teva to Host R&amp;D Day on Wednesday, November 11 in New York City</title><guid>12df8b0d-a2d1-4ae3-a478-10969058c429</guid><description /><link>https://ir.tevapharm.com/news-and-events/press-releases/press-release-details/2026/Teva-to-Host-RD-Day-on-Wednesday-November-11-in-New-York-City/default.aspx</link><pubDate>Mon, 12 Oct 2026 17:45:00 -0400</pubDate></item><item><title>Teva Announces U.S. Food and Drug Administration (FDA) Approval of WELTRUZA™ (Olanzapine) For Extended-Release Injectable Suspension, as the First and Only Once-Monthly Subcutaneous Injectable Olanzapine for Adults with Schizophrenia</title><guid>143141f6-1a3d-420f-b3cf-49be317d1382</guid><description /><link>https://ir.tevapharm.com/news-and-events/press-releases/press-release-details/2026/Teva-Announces-U-S--Food-and-Drug-Administration-FDA-Approval-of-WELTRUZA-Olanzapine-For-Extended-Release-Injectable-Suspension-as-the-First-and-Only-Once-Monthly-Subcutaneous-Injectable-Olanzapine-for-Adults-with-Schizophrenia/default.aspx</link><pubDate>Fri, 09 Oct 2026 07:00:00 -0400</pubDate></item><item><title>Teva Presents New Efficacy and Safety Data with Ecopipam, an Investigational Treatment for Pediatric Patients with Tourette Syndrome</title><guid>8c950dfd-abf5-423f-8416-00d7aebdba41</guid><description /><link>https://ir.tevapharm.com/news-and-events/press-releases/press-release-details/2026/Teva-Presents-New-Efficacy-and-Safety-Data-with-Ecopipam-an-Investigational-Treatment-for-Pediatric-Patients-with-Tourette-Syndrome/default.aspx</link><pubDate>Fri, 02 Oct 2026 08:00:00 -0400</pubDate></item><item><title>Journal of Child Neurology Publishes Review Highlighting Dopamine’s Role in Tourette Syndrome and Ecopipam’s Selective D1 Receptor Mechanism for Tourette Syndrome in Pediatric Patients</title><guid>9ac8290c-1745-4055-9697-bb12f85d1784</guid><description /><link>https://ir.tevapharm.com/news-and-events/press-releases/press-release-details/2026/Journal-of-Child-Neurology-Publishes-Review-Highlighting-Dopamines-Role-in-Tourette-Syndrome-and-Ecopipams-Selective-D1-Receptor-Mechanism-for-Tourette-Syndrome-in-Pediatric-Patients/default.aspx</link><pubDate>Fri, 02 Oct 2026 08:00:00 -0400</pubDate></item></channel></rss>